The treatment goal in type 2 diabetes (T2D) is to keep the blood glucose within a target range. In the early stages of diabetes, the treatment may consist entirely of oral antidiabetics (OAD), which may be preferable over injectables for some people. However, previously published systematic reviews found a low OAD adherence and that the adherence differs between different OAD types. These systematic reviews were performed before 2015, and several new OADs have been marketed since then. Thus, a systematic review will be undertaken to review the newest studies on adherence to oral second line antidiabetics in people with T2D.
|Konference||The Scandinavian Conference on Health Informatics (SHI) 2022|
|Periode||22/08/2022 → 24/08/2022|
|Navn||Scandinavian conference on health informatics|